Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Jun;85(6):1260-1269.
doi: 10.1111/bcp.13892. Epub 2019 Mar 28.

Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France

Damien Driot  1   2 , Emilie Jouanjus  2   3 , Stéphane Oustric  1   2 , Julie Dupouy  1   2 , Maryse Lapeyre-Mestre  2   3   4
Affiliations
Observational Study

Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France

Damien Driot et al. Br J Clin Pharmacol. 2019 Jun.

Abstract

Aims: The aim of this study was to assess the use and factors associated with the misuse of gabapentin and pregabalin in the general French population, through a cohort study in the EGB (General Sample of Beneficiaries), a national representative sample of the French general population.

Methods: New users of gabapentin and pregabalin were identified from June 2006 to December 2014, and new users of duloxetine served as control group. Misuse was defined as a use of higher daily doses than recommended. Cox proportional hazard regression models were performed to identify associated factors of misuse.

Results: Misuse was more frequent in the 8692 new users of pregabalin (12.8%) than in the 1963 gabapentin (6.6%) or the 3214 duloxetine new users (9.7%) (P < 0.001). Factors associated with misuse were pregabalin (hazard ratio [HR] 1.48; 95% confidence interval [CI] [1.29-1.69]), age (HR[18-45] versus > 70 years 1.98 [1.70-2.31] and HR[58-70] versus > 70 years 1.25 [1.06-1.47]), multiple prescribers (HR2 or 3 versus 1 prescriber 1.29 [1.15-1.45]; HR4 or more versus 1 prescriber 1.54 [1.30-1.83]), cancer (1.28 [1.11-1.47]), multiple sclerosis (1.53 [1.07-2.18]), neuropathy (1.85 [1.19-2.89]), depression (1.26 [1.07-1.49]) and methadone (2.61 [1.16-5.84]). After this first episode of drug misuse, 11.6% of gabapentin and 10.7% of pregabalin misusers developed a primary addiction.

Conclusion: In a cohort of new users, misuse is more likely to occur in new users of pregabalin, with different associated factors of misuse compared to gabapentin and duloxetine. Health professionals and prescribers must be aware of this misuse potential, which could lead to abuse and dependence.

Keywords: abuse; addiction; gabapentin; misuse; pregabalin.

PubMed Disclaimer

Conflict of interest statement

There are no competing interests to declare.

Figures

Figure 1
Figure 1
Cumulative incidence of misuse over time (years) according to the use of pregabalin, gabapentin or duloxetine (new users), presented as Kaplan‐Meier curves. Number of outcomes and censored subjects during the overall observation period, and within the first two years after study entry
See this image and copyright information in PMC

References

    1. Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia—An overview of Cochrane reviews. Cochrane Database Syst Rev. 2013;11:CD010567. - PMC - PubMed
    1. Shmagel A, Ngo L, Ensrud K, Foley R. Prescription medication use among community‐based US adults with chronic low back pain: A cross‐sectional population based study. J Pain. 2018;19(10):1104‐1112. - PMC - PubMed
    1. Alexander SP, Peters JA, Kelly E, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Ligand‐gated ion channels. Br J Pharmacol. 2017;174:S130‐S159. - PMC - PubMed
    1. Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: A systematic review and meta‐analysis of randomized controlled trials. Epilepsia. 2011;52(4):826‐836. - PubMed
    1. Schifano F, D'Offizi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80(2):118‐122. - PubMed

Publication types

MeSH terms